Argentine President Alberto Fernandez at an Aug. 12, 2020 press conference (Juan Mabromata/Pool via AP)

Covid-19 roundup: Sor­ren­to threat­ens to sue crit­ic of their coro­n­avirus ‘cure’; No­vavax signs with SK bio­science

Sor­ren­to Ther­a­peu­tics has come un­der fire for how they’ve char­ac­ter­ized their Covid-19 re­search, tak­ing heat in May from re­searchers, bio-ethi­cists and even some in­vestors for claim­ing they had a Covid-19 “cure.” Now, Sor­ren­to is threat­en­ing “le­gal ac­tion” against an in­vest­ment re­search firm crit­i­cal of its work.

Hin­den­burg Re­search first crit­i­cized the com­pa­ny for the “cure” claim in a lengthy re­port in May, and then on Tues­day, wrote on Twit­ter that CEO Hen­ry Ji’s claims and CN­BC cov­er­age of a spit test Sor­ren­to li­censed from Co­lum­bia Uni­ver­si­ty had more than dou­bled its stock val­ue. Hin­den­burg cit­ed an un­named Co­lum­bia of­fi­cial who called Sor­ren­to’s claims “a com­plete joke.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.